4.6 Review

Race and Genetics in Congenital Heart Disease: Application of iPSCs, Omics, and Machine Learning Technologies

期刊

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2021.635280

关键词

congenital heart disease; iPSC; disease modeling; genomics; race; disparity

资金

  1. National Institutes of Health [K08HL148540, F30HL156478, R01HL126527, R01 HL130020, R01 HL146690]
  2. American Heart Association [17MERIT3361009]

向作者/读者索取更多资源

Congenital heart disease is a multifaceted cardiovascular anomaly that occurs before birth and is influenced by racial disparities. Using induced pluripotent stem cells for cardiovascular disease modeling is a novel approach that may help uncover genetic variants and racial disparities in congenital heart disease.
Congenital heart disease (CHD) is a multifaceted cardiovascular anomaly that occurs when there are structural abnormalities in the heart before birth. Although various risk factors are known to influence the development of this disease, a full comprehension of the etiology and treatment for different patient populations remains elusive. For instance, racial minorities are disproportionally affected by this disease and typically have worse prognosis, possibly due to environmental and genetic disparities. Although research into CHD has highlighted a wide range of causal factors, the reasons for these differences seen in different patient populations are not fully known. Cardiovascular disease modeling using induced pluripotent stem cells (iPSCs) is a novel approach for investigating possible genetic variants in CHD that may be race specific, making it a valuable tool to help solve the mystery of higher incidence and mortality rates among minorities. Herein, we first review the prevalence, risk factors, and genetics of CHD and then discuss the use of iPSCs, omics, and machine learning technologies to investigate the etiology of CHD and its connection to racial disparities. We also explore the translational potential of iPSC-based disease modeling combined with genome editing and high throughput drug screening platforms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据